A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer (neoMONARCH)
The purpose of this study is to evaluate the biological effects of abemaciclib in combination with anastrozole and compare those to the effects of abemaciclib alone and anastrozole alone in the tumors of postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative breast cancer.
The results of this study are not yet available.
Your participation could last up to 10 months depending on how you and your tumor respond.
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participant must have a diagnosis of HR+, HER2- breast cancer
Participant must be postmenopausal
Participant must not have bilateral invasive breast cancer or inflammatory breast cancer
Participant must not have metastatic breast cancer (local spread to axillary lymph nodes is permitted)
Participant must not have prior systemic therapy or radiotherapy for invasive or non-invasive breast cancer in the same breast as currently being treated
Participant must not have prior radiotherapy to the ipsilateral chest wall for any malignancy
Participant must not have prior anti-estrogen therapy